02.04.2012 07:05 Uhr, Quelle: Wallstreet online

ABLYNX RECEIVES MILESTONE PAYMENT AS COLLABORATOR RECEIVES IND APPROVAL FOR A NANOBODY IN ONCOLOGY

GHENT, Belgium, 2 April 2012 - Ablynx [Euronext Brussels: ABLX] today announced that it has received a EUR400,000 milestone payment from its collaboration with Novartis. The payment was triggered by the approval of an Investigational New Drug …

Weiterlesen bei Wallstreet online